Magnetic Resonance Imaging Reveals a Pronounced Treatment Response of a Isocitrate Dehydrogenase− and B-Raf Proto-Oncogene−Wildtype Epithelioid Glioblastoma
- 1 July 2019
- journal article
- research article
- Published by Elsevier in World Neurosurgery
- Vol. 127, 213-215
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E MutationInternational Journal of Molecular Sciences, 2018
- Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysisBrain Pathology, 2017
- Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal diseaseOncology Reports, 2017
- Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor TaxonomyActa Neuropathologica, 2016
- The survival significance of a measurable enhancing lesion after completing standard treatment for newly diagnosed glioblastomaJournal of Clinical Neuroscience, 2016
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- Epithelioid GBMs Show a High Percentage of BRAF V600E MutationAmerican Journal of Surgical Pathology, 2013
- Temozolomide for Adult Brain Stem Glioblastoma: Case Report of a Long-Term SurvivorInternational Journal of Neuroscience, 2010
- Complete response after one cycle of temozolomide in an elderly patient with glioblastoma and poor performance statusJournal of Neuro-Oncology, 2008
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005